Announcements Trials
Browse Landscape

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 118Observational 3Expanded_access 1

Sponsor

Cancer Type

Genitourinary 3Breast 3NET 2Endocrine 2Gastrointestinal 1

Conditions

Breast Neoplasms 3Carcinoma, Renal Cell 1

Interventions

Surveys and Questionnaires 79Blood Specimen Collection 67palbociclib 40Trastuzumab 34Drug Therapy 30Letrozole 29Anastrozole 27Radiotherapy 26Immunohistochemistry 26Mastectomy, Segmental 22Amplified Fragment Length Polymorphism Analysis 22Fulvestrant 21Biopsy 21exemestane 20Tamoxifen 20Interviews as Topic 20Gene Expression Profiling 20Magnetic Resonance Spectroscopy 19ribociclib 18Specimen Handling 18Mastectomy 18Neoadjuvant Therapy 17Paclitaxel 16High-Energy Shock Waves 16Capecitabine 16trastuzumab deruxtecan 15Mammography 15Psychiatric Rehabilitation 14Polymerase Chain Reaction 13Observation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Everolimus × Breast × Clear all
NCT04212702 2021-01-12

ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments

National Taiwan University Hospital

Unknown
123 enrolled
Breast

Breast Neoplasms

NCT02809404 2017-10-16

SPOT

Radboud University Medical Center

Completed
75 enrolled
BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell

NCT02023359 2015-12-29

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Novartis

Completed
7 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡